Nurix Therapeutics, Inc.
Nurix Therapeutics (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation medicines for cancer and inflammatory diseases. Its wholly owned clinical pipeline includes bexobrutideg, a BTK degrader, and zelebrudomide, which degrades BTK and the transcription… From the company’s description.
Over the twelve months to Aug 31, 2026, Nurix Therapeutics, Inc. reported revenue of $701.94M, up 738.8% from a year earlier, and net income of $294.88M. Its operating margin was 41.3%, and operations generated $379.31M in cash. In fiscal 2025, it reported revenue of $83.98M, up 54.0% from fiscal 2024, and a net loss of $264.46M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nurix Therapeutics, Inc. does
In the company’s own words
Nurix Therapeutics (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation medicines for cancer and inflammatory diseases. Its wholly owned clinical pipeline includes bexobrutideg, a BTK degrader, and zelebrudomide, which degrades BTK and the transcription factors Ikaros and Aiolos, both being studied for B-cell malignancies, as well as NX-1607, a CBL-B inhibitor being studied in solid tumors. Nurix also advances preclinical protein degraders and degrader antibody conjugates, and uses its DEL-AI discovery platform in partnered programs with Gilead, Sanofi and Pfizer, including drug candidates for inflammatory conditions and Type 2 inflammation. The company retains certain U.S. co-development, co-commercialization and profit-sharing options under these collaborations. Its wholly owned and partnered research programs address oncology, inflammation and immunology, with discovery work supported by machine-learning tools and DNA-encoded library screening. As of November 30, 2025, Nurix had received $482 million in non-dilutive collaborator funding and was eligible for potential future fees and milestone payments.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- November
- CIK
- 1549595
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nurix Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nurix Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nurix Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nurix Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nurix Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”